Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells

Cancer Gene Therapy

Volumn 4, Issue 2, 1997, Pages 97-104

  Clary, Bryan M ^a   Coveney, Eamonn C ^a   Philip, Ramila ^b   Blazer III, Dan G ^a   Morse, Michael ^a   Gilboa, Eli ^a   Lyerly, H Kim ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Applied Immune Sciences   (United States)

Author keywords

Cytokine; Gene therapy; Immunotherapy; Pancreatic cancer; Tumor vaccines

Indexed keywords

HLA ANTIGEN CLASS 1; INTERLEUKIN 2; RECOMBINANT PROTEIN;

ADENOCARCINOMA; ANIMAL; ARTICLE; C57BL MOUSE; CELL CULTURE; CELL TRANSPLANTATION; DISEASE MODEL; DRUG EFFECT; GENE THERAPY; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MALE; METABOLISM; METHODOLOGY; MOUSE; PAGET NIPPLE DISEASE; PANCREAS TUMOR; SURVIVAL RATE;

ADENOCARCINOMA; ANIMALS; CARCINOMA, DUCTAL, BREAST; CELL TRANSPLANTATION; DISEASE MODELS, ANIMAL; GENE THERAPY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MALE; MICE; MICE, INBRED C57BL; PANCREATIC NEOPLASMS; RECOMBINANT PROTEINS; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 0031087463     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Boring C, Squires T, Tong T. Cancer statistics 1993. CA Cancer J Clin. 1993;43:7-26.
2. Warshaw W, Swanson R. Pancreatic cancer in 1988. Ann Surg. 1988;208:541-553.
3. Connolly M, Dawson P, Michelassi F, et al. Survival in 1001 patients. Ann Surg. 1987;206:366-373.
4. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59:2006-2010.
5. Gunderson L, Martin J, Knols L. Intraoperative and externl beam irradiation ± 5-FU for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 1987;13: 319-329.
6. Tepper J, Shipley W, Warshaw A. The role of misonidazole combined with intraoperative radiation therapy in the treatment of pancreatic carcinoma. J Clin Oncol. 1987;5: 579-584.
7. Hanna M, Ransom J, Pomato N, et al. Active specific immunotherapy of human colorectal carcinoma with an autologous tumor cell/Bacillus Calmette-Guérin vaccine. Ann NY Acad Sci. 1993;690:135-146.
8. Schirrmacher V, Schlag P, Liebrich W, et al. Specific immunotherapy of colorectal carcinoma with Newcastle-disease virus-modified autologous tumor cells prepared from resected liver metastases. Ann NY Acad Sci. 1993; 690:364-366.
9. Ioannides C, Platsoucas C, O'Brian C, et al. Viral oncosylates in cancer treatment: immunological mechanisms of action. Anticancer Res. 1989;9:535-544.
10. Forni G, Giovarelli M, Santoni A, et al. Tumor inhibition by interleukin-2 at the tumor/host interface. Biochim Biophys Acta. 1986;865:307-327.
11. Bubenik J, Perlmann P, Indrova M, et al. Growth inhibition of an MC-induced mouse sarcoma by TCGF (IL2) containing preparation. Cancer Immunol Immunother. 1983;14:205-206.
12. Aoki T, Tashiro K, Miyatake S, et al. Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Natl Acad Sci USA. 1992;89: 3850-3853.
13. Connor J, Bannerji R, Saito S, et al. Regression of bladder tumors in mice treated with interleukin-2 gene-modified tumor cells. J Exp Med. 1993;177:1127-1134.
14. Fearon E, Pardoll D, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an anti-tumor response. Cell. 1990;60:397-403.
15. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539-3543.
16. Gansbacher B, Zier K, Daniels B, et al. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med. 1990;172:1217-1224.
17. Gansbacher B, Bannerji R, Daniels B, et al. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting anti-tumor immunity. Cancer Res. 1990;50:7820-7825.
18. Golumbek P, Lazenby A, Levitsky H, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991;254:713-716.
19. Porgador A, Tzehoval E, Katz A, et al. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res. 1992;52:3679-3686.
20. Porgador A, Tzehoval E, Vadai E, et al. Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon-γ genes. J Immunother. 1993;14:191-201.
21. Saito S, Bannerji R, Gansbacher B, et al. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res. 1994;54:3516-3520.
22. Vieweg J, Rosenthal R, Bannerji R, et al. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res. 1994; 54:3516-3520.
23. Hamaoka T, Fujiwara H. Phenotypically and functionally distinct T cell subsets in anti-tumor responses. Immunol Today. 1987;8:267-269.
24. Greenberg, P. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol. 1991;49:281-355.
25. Corbett T, Roberts B, Liopold W, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 1984;44:717-726.
26. Philip R, Clary B, Brunette E, et al. Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer. Clin Cancer Res. 1996;2:59-68.
27. Cullen, B. Trans-activation of human immunodeficiency virus occurs via bimodal mechanism. Cell. 1986;46:973-982.
28. Armentano D, Yu S, Kantoff P, et al. Effect of internal viral sequences on the utility of retroviral vectors. J Virol. 1987;61:1647-1650.
29. Vieweg J, Boczkowski D, Roberson K, et al. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res. 1995;55:2366-2372.
30. Van Pel A, Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci USA. 1982;79:4718-4722.
31. Zinkernagel R, Doherty P. MHC-restricted cytotoxic T cell: studies on the biological role of polymorphic major transplantation antigens determining T cell restriction - specificity, function, and responsiveness. Adv Immunol. 1979;27:51-106.
32. Finn O. Tumor-rejection antigens recognized by T-lymphocytes. Curr Opin Immunol. 1993;5:701-708.
33. Peace D, Smith J, Disis M, et al. T cell recognition of transforming proteins encoded by mutated ras protooncogenes. J Immunol. 1991;146:2059-2065.
34. Rosenberg S, Yang J, Topalian S, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271:907-913.